Study evaluating the efficacy, safety, and tolerability of the study drug compared to placebo in female subjects, diagnosed with major depressive disorder

This medicine may reduce a participant's innate high-sensitivity to depression and that results in low mood, increased emotionality, and affect instability.

Individuals with major depressive disorder (MDD) may show elevated plasma levels of cortisol (a "stress hormone"). This hormone may play a role in regulating response to stress, and may be involved in MDD. It is also play a role in the release of  adrenocorticotrophic hormone (ACTH) from the pituitary gland and, consequently, the release of glucocorticoids from the adrenal cortex.

This medication is being studied to treat depression.

The study will last approximately 13 weeks. Patients' emotional and physiological responses will be comprehensively monitored.

You may be eligible to participate in this study if you:

• Are a female outpatients aged 18-64 years of age, inclusive
• Have a current depression episode for at least 4 weeks, but for not greater than 24 months
• Have not had a diagnosis of anorexia nervosa or bulimia
• Have not failed depression medicines from 2 different classes

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.